Pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) revealed today it is pursuing legal action against Hims & Hers Health Inc (NYSE:HIMS) for alleged patent infringement, after the telehealth giant introduced a weight-loss pill with the same active ingredient as its Wegovy drug -- priced at $149 -- at a much lower starting price of $49. Hims & Hers Health stopped offering the medication on Saturday, following threats of legal action from the U.S. Food and Drug Administration (FDA) and Novo Nordisk. The FDA als ...

The Danish drugmaker's patent lawsuit is the company's latest effort to shore up its place in the booming weight-loss drug market. ...

• Hims & Hers Health stock is at significant support. What’s pressuring HIMS?What HappenedLast Thursday, Hims & Hers Health announced an expansion of its weight loss specialty by enabling providers to prescribe a Compounded Semaglutide Pill with the same active ingredient as Novo Nordisk’s Wegovy, at a special introductory offer starting at just $49 for the first month.Novo Nordisk said that Hims & Hers will unlawfully mass-market an unapproved, inauthentic, and untested knockoff semaglutide pill.On Friday ...

Shares of Hims & Hers crashed to new 52-week lows on Monday, under the weight of much uncertainty. HIMS stock is dropping. See the chart and price action here. Federal Crackdown: FDA & DOJOne catalyst for the crash was Hims’ recent aggressive attempt to launch a compounded oral semaglutide pill — a copycat of Novo Nordisk A/S’s (NYSE:NVO) newly approved oral Wegovy. The response from Washington was swift and severe:Under regulatory pressure, Hims & Hers did a U-turn on Saturday and announced it would stop o ...

Core Insights - Hims & Hers Health's stock dropped 25% after the company announced it would cease selling its compounded semaglutide weight-loss pill, just days after its launch, due to legal action from Novo Nordisk [1][1][1] - Novo Nordisk has filed a lawsuit against Hims & Hers, seeking to permanently ban the sale of unapproved compounded drugs that infringe on its patents and is pursuing damages [1][1][1] - Hims & Hers has faced significant stock depreciation, losing over 60% of its value in the past 12 months, while Novo Nordisk's shares have decreased by approximately 40% during the same period [1][1][1] Company Developments - Hims & Hers announced the discontinuation of its compounded weight-loss pill, which was marketed as having the same active ingredient as Novo Nordisk's Wegovy, following legal threats from Novo Nordisk [1][1][1] - The lawsuit from Novo Nordisk is described by Hims & Hers as a "blatant attack" on Americans who rely on compounded medications, indicating the company's intent to continue advocating for access to these treatments [1][1][1] Industry Context - The FDA has indicated plans to restrict the use of GLP-1 active ingredients in compounded weight-loss medications, specifically mentioning Hims & Hers in its statement [1][1][1] - Eli Lilly is anticipated to receive FDA approval for its own weight-loss pill later this year, which could further impact competition in the weight-loss drug market [1][1][1]

Hims & Hers Health (NYSE: HIMS) stock crashed 25% through 10:45 a.m. ET Monday morning after an eventful weekend. On Thursday, the telehealth company announced it would begin selling a compounded version of Wegovy in pill form, for $49 per month. Hims & Hers doesn't manufacture "Wegovy." Novo Nordisk (NYSE: NVO) does, charging $149 per month for Wegovy (Ozempic) in pill form, and $199 injectable. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to b ...

Hims & Hers dropped its plan for a knockoff Wegovy weight-loss pill - Fast Company[Try our mini crossword with a business twist: Play Fast Company Mini Crossword]LOGIN[SUBSCRIBE]- [INNOVATION FESTIVAL]- [Video]- [Podcasts]- [Games]- [Work Life]- [Leadership]- [News]- [Design]- [Tech]- [Premium]| [Custom Studio]- [Texas A&M University]- [IBM]BY [Associated Press]Listen to this Article [More info]0:00 / 0:00[Telehealth company Hims & Hers] dropped its plan to offer a knockoff version of the [weight-loss pill ...

Shares of Hims & Hers Health (NYSE:HIMS) plunged 22% at market open on Monday, February 9. ...

Hims & Hers Stock Plunges 24%. Its Weight-Loss Drug Strategy Backfired. - Barron'sSkip to Main ContentThis copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.# Hims & Hers Stock Plunges 24%. Its Weight-Loss Drug Strategy Backfired.By [George Glover]ShareResize---ReprintsIn this a ...

Morning Trade Live. Let's focus on the latest development in the weight loss drug trade. Novo Nordisk is high this morning and hims and hers is moving in the other direction quite substantially.After Hims pulled its generic wegovy pill. Both stocks have had a rough start to 2026, but today's move is a bright spot for Novo investors, so that is the focus of the morning trade. Joining us now for a closer look is Marley Kayden.Very good morning. Happy Monday Marley. So a nice shot in the arm now for Novo.It ne ...